Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
CYAD (Celyad Oncology SA) provides a centralized hub for tracking developments in clinical-stage cell therapies and immuno-oncology innovations. This resource aggregates essential updates including trial progress, regulatory milestones, and strategic partnerships critical for evaluating the company's position in cancer treatment research.
Investors and researchers will find curated press releases detailing CYAD's NKR-T cell programs, manufacturing advancements, and collaborative initiatives with institutions like Dartmouth College. The collection emphasizes factual reporting on phase transitions, financial disclosures, and operational updates without speculative commentary.
Content spans clinical trial authorizations, intellectual property developments, and executive leadership changes. Regular updates ensure stakeholders maintain current awareness of CYAD's progress in translating cell-based therapies from laboratory research to clinical applications.
Bookmark this page for streamlined access to verified CYAD developments. Combine periodic reviews with real-time monitoring for comprehensive analysis of the company's evolving role in advanced cancer treatment solutions.
Celyad Oncology (CYAD) provided updates on its CAR T therapies during a recent research and development day. The Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma showed promising dose-dependent engraftment with no reported Graft-versus-Host disease. The IND application for CYAD-203, a first-in-class IL-18-armored CAR T candidate, is expected by mid-2022. Additionally, CYAD-101 demonstrated good tolerability in advanced metastatic colorectal cancer and will soon enter the KEYNOTE-B79 Phase 1b trial. The company also acquired a license for an antibody targeting TAG-72.
Celyad Oncology announced a Research & Development webinar on July 20th, 2021, at 11:30 a.m. EDT, focusing on advancements in its pipeline. The leadership team will discuss preclinical allogeneic CAR T assets using shRNA technology and updates on clinical programs, including the CYAD-211 candidate for relapsed/refractory multiple myeloma and CYAD-101 for metastatic colorectal cancer. Investors can register for the live webcast on the Celyad website, with a replay available afterward.
Celyad Oncology, a clinical-stage biotechnology company focused on CAR T therapies for cancer, announced that Dr. David Gilham will participate in a panel discussion titled “Cell Therapies in the Next Decade” on July 14, 2021, at the William Blair Biotech Focus Conference. The event will be held virtually from July 14-15, and the management team will also engage in one-on-one investor meetings. A live audio webcast of the discussion will be available on the company’s website. Celyad continues to develop innovative cancer treatments through its extensive CAR T pipeline.
Celyad Oncology (CYAD) announced a capital increase of 306,800 new shares on June 30, 2021, through Lincoln Park Capital Fund, LLC and Jefferies LLC. This transaction raises the company's share capital to 53,912,224.33 EUR, now represented by 15,493,956 shares. The number of shares with single voting rights totals 13,125,931, while shares with double voting rights amount to 2,368,025. The total of diluted shares is 17,416,379. This disclosure complies with Belgian law regarding the transparency of major participations in trading companies.
Celyad Oncology has announced promising preliminary data from the Phase 1 IMMUNICY-1 trial of CYAD-211 for treating relapsed/refractory multiple myeloma. The treatment was generally well-tolerated at the first two dose levels, with no Graft-versus-Host Disease and two partial responses among five evaluable patients. All patients showed cell engraftment after the second dose. Management plans to provide additional results in the second half of 2021 and highlighted the potential of shRNA technology for allogeneic CAR T therapies.
Celyad Oncology announced a capital increase on May 31, 2021, issuing 182,000 new shares through its Open Market Sale Agreement with Jefferies LLC. This brings the company's total share capital to 52,844,560.33 EUR and increases total shares to 15,187,156. Following the increase, the total number of diluted shares stands at 17,114,912. This move follows Article 15 of Belgian law concerning the disclosure of major participations in publicly traded companies.
Celyad Oncology SA, focused on CAR T therapies for cancer, will present at multiple conferences in June 2021. The presentations will be led by CEO Filippo Petti at events including the Jefferies Virtual Healthcare Conference, William Blair Annual Growth Stock Conference, and JMP Securities Life Sciences Conference. Notably, funding from Walloon Region has been received to support ongoing CAR T therapy programs. Celyad is developing both allogeneic and autologous CAR T candidates targeting hematological malignancies and solid tumors.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) received a transparency notification indicating that Victory Capital Management Inc. has crossed the 5% threshold in voting rights, holding 713,214 shares (4.11% of total shares) as of May 13, 2021. The notification reflects a downward crossing of the statutory threshold due to acquisition or disposal of voting securities. Victory Capital operates through multiple controlled undertakings, and it can exercise voting rights at its discretion.
Celyad Oncology has announced positive initial results from the Phase 1 IMMUNICY-1 trial of its anti-BCMA CAR T candidate, CYAD-211, focused on relapsed/refractory multiple myeloma. The first dose-level cohort showed no Grade ≥ 3 treatment-related adverse events or Graft-versus-Host disease. Notably, a confirmed partial response was observed in one patient receiving a low dose of 30x106 cells. The trial aims to assess the safety and efficacy of CYAD-211, utilizing a non-gene editing technology that minimizes safety risks. Results will be presented at the upcoming EHA Virtual Congress 2021.
Celyad Oncology has provided updates on its clinical trials and financial results for Q1 2021. The Phase 1 IMMUNICY-1 trial for CYAD-211, an allogeneic CAR T candidate, is ongoing with no safety issues reported. Additionally, the alloSHRINK trial for CYAD-101 is progressing, with preliminary data expected mid-2021. The company has appointed new key personnel and entered a $40 million equity purchase agreement with Lincoln Park Capital. As of March 31, 2021, Celyad had €12.2 million in cash, enough to fund operations until mid-2022.
